Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

The OHG leadership shake-up comes amid a larger period of transition for Omnicom. In early December, the company laid out its ...

While Ionis has gained several FDA nods in its 35 years in existence, Tryngolza will be the first medicine the Carlsbad, ...

In this week’s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City ...

Christmas seems to have come early for Klick Health, with a slew of new leaders arriving under the life sciences marketing ...

Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to ...

Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. The new ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...